

**Table 1.** Reported cases of BPs' use prior to and/or during pregnancy/lactation

Study	No. of pregnancies	Mean age at conception	BP	Dose	Duration of BP treatment	Administration conception	Indication	Concomitant treatments	Live births	Spontaneous abortions	Voluntary abortions	Median gestational age (ws)	Median birth weight (g)	Congenital malformation	Adverse infant outcome	Breast feeding	Adverse infant outcome during breast-feeding
Ornoy et al <sup>6</sup>	24	NR	alendronate	NR	NR	0-6 ms before (8) 0-8 ws during (15) 0-21 ws during (1)	ARD (13), OP(5), other (6)	CS (13)	19 (79.1%)	5 (20,8)	0	38	2910	0	NR	NR	-
Levy et al <sup>7</sup>	21	32.4	alendronate (12), etidronate (5), risedronate (2), pamidronate (2)	NR	NR	0-3 ms during (15), 3ms before (6)	CS induced OP (15), OP (5), metastatic cancer (1)	CS (15), AZA+SFZ (17)	18 (85.7%)	2 (9.5%)	1 (4.8%)	38.7	3100	1 (Apert syndrome)	2 (1pre-mature birth, 1 jaundice)	NR	-
Losada et al <sup>8</sup>	10	35	alendronate, pamidronate, clodronate, neridronate	NR	NR	before or during	CS induced OP (7), primary OP (1), pelvic fracture (1), femoral avascular necrosis (1)	AZA(2), SFZ (1), CS(2), cyclosporine (1), hydroxychloroquine (1)	9 (90%)	1 (10%)	0	38	2890	2 [1ventricular septal defect (clodronate), 1 kidney & cardiac malformation (alendronate)]	2 (1 pre-mature birth, 1 distress syndrome)	NR	-
Chan et al <sup>9</sup>	4	29.5	pamidronate	iv 1mg/kg for 3 ds/4-6 ms	46ms 26ms	3ms before 3ms before 48ms before	McCune-Albright	no	4 (100%)	0	0	38	2500	0	0	Yes (18 ms) Yes	0 0
				iv 1mg/kg/2ms	19ms	21ms before	OI type IV					34	2270		Yes (6 ws)	0	

d(s): days; w(s): weeks; m(s): months; y(s): year(s); Ref: Reference; BP: bisphosphonate; prg: pregnancy; NR: not reported; iv: intravenous; p.os.: orally; OP: osteoporosis; ARD: autoimmune rheumatic disease; OI: osteogenesis imperfecta; PLOP: pregnancy/lactation associated osteoporosis; CS: corticosteroids; AZA: azathioprine; SFZ: sulfasalazine; CH: chemotherapy.

**Table 1.** (continue) Reported cases of BPs' use prior to and/or during pregnancy/lactation

Study	No. of pregnancies	Mean age at conception	BP	Dose	Duration of BP treatment	Administration conception	Indication	Concomitant treatments	Live births	Spontaneous abortions	Voluntary abortions	Median gestational age (ws)	Median birth weight (g)	Congenital malformation	Adverse infant outcome	Breast feeding	Adverse infant outcome during breast-feeding
Munns et al <sup>10</sup>	2	17.4	pamidronate	iv 1mg for 3 ds/4 ms	5 ys	Until prg	OI type I OI type IV	no	2 (100%)	0	0	38	3230	1 (Bilateral talipes equinovarus)	1 (Transient hypocalcaemia)	NR	-
Hassen-Zro-ur et al <sup>11</sup>	1	30	alendronate pamidronate	p.os. 10 mg/d iv 90 mg/4 ms	6 ms 1y	Before conception	OI type I	NR	1 (100%)	0	0	39	4000	0	0	Yes (3 ms)	1 [Transient hypocalcemia (2 ms of age)]
Harsch et al <sup>12</sup>	1 (triple)	30	alendronate	NR	3 ys	Until prg	PLOP	no	3 (100%)	0	0	NR	NR	0	0	NR	-
Athimulam et al <sup>13</sup>	1 (twin)	34	alendronate	NR	NR	Until prg	PLOP	no	2 (100%)	0	0	36	NR	0	0	NR	-
Vujasinovic-Stupar et al <sup>14</sup>	2	33 35	etidronate	p.os. 400mg/d for 14d/3m	1.5ys 3.5ys	3m before 3m before	PLOP	calcitonin	2 (100%)	0	0	Full term (>37) Full term (>37)	NR NR	0 0	0 0	NR	-
Cabar et al <sup>15</sup>	1	30	pamidronate	iv 1mg for 3 ds/4ms	3.5 ys	1m before	idiopathic hyperphosphatasia	no	1 (100%)	0	0	36	3130	0	0	NR	-
Rutgers-Verhage et al <sup>16</sup>	1	49	alendronate	p.os. 0.12 mg/kg/d	NR	Until prg	presumed postmenopausal OP	NR	1 (100%)	0	0	36	2390	0	1 [at one y of age weighed 8 kg (10 <sup>th</sup> centile)]	NR	-
Mastaglia et al <sup>17</sup>	1	21	pamidronate	iv 60 mg/3 ms	1 y	3 infusions before & 1 during first trimester	Gaucher's disease type 1	intermittent enzyme replacement therapy	1 (100%)	0	0	37	2230	0	0	Yes (12 ms)	0

d(s): days; w(s): weeks; m(s): months; y(s): year(s); Ref: Reference; BP: bisphosphonate; prg: pregnancy; NR: not reported; iv: intravenous; p.os.: orally; OP: osteoporosis; ARD: autoimmune rheumatic disease; OI: osteogenesis imperfecta; PLOP: pregnancy/lactation associated osteoporosis; CS: corticosteroids; AZA: azathioprine; SFZ: sulfasalazine; CH: chemotherapy.

**Table 1.** (continue) Reported cases of BPs' use prior to and/or during pregnancy/lactation

Study	No. of pregnancies	Mean age at conception	BP	Dose	Duration of BP treatment	Administration conception	Indication	Concomitant treatments	Live births	Spontaneous abortions	Voluntary abortions	Median gestational age (ws)	Median birth weight (g)	Congenital malformation	Adverse infant outcome	Breast feeding	Adverse infant outcome during breast-feeding
Biswas et al <sup>18</sup>	2	NR	alendronate	NR	NR	First trimester (1), 2 ms before (1)	NR	NR	2 (100%)	0	0	NR	NR	0	0	NR	-
Dunlop et al <sup>19</sup>	1	28	aminopyridine BP	iv 30 mg	once	34 <sup>th</sup> gestational w		CH + CS	1 (100%)	0	0	36	3060	0	1 (transient hypocalcaemia)	no	-
Illidge et al <sup>20</sup>	1	42	pamidronate	iv NR	once	28 <sup>th</sup> gestational w	Malignant hypercalcaemia (Metastatic breast cancer)	Morphine + CS	1 (100%)	0	0	29	1412	0	1 (transient hypocalcaemia)	no	-
Andreadis et al <sup>21</sup>	1	34	zoledronic acid	iv 4 mg/28 ds	-	2 <sup>nd</sup> and 3 <sup>rd</sup> trimester		CH + Radiotherapy (28Gy) + tamoxifen	1 (100%)	0	0	35	2070	0	0	no	-
Culbert et al <sup>22</sup>	1	40	pamidronate	iv NR	once	28 <sup>th</sup> gestational w		CH	1 (100%)	0	0	NR	NR	0	0	no	-
Simionski et al <sup>23</sup>	1	39	pamidronate	iv 30 mg/m	6 ms	Lactation period	Reflex sympathetic dystrophy	no	1 (100%)	0	0	40	NR	-	-	Yes (6 ms)	0
Total fetuses exposed in utero	78	32.2							69 (88.5%)	8 (10.8%)	1 (1.4%)	36.5	2707				
Total breast-fed infants	7																6.1 ms

d(s): days; w(s): weeks; m(s): months; y(s): year(s); Ref: Reference; BP: bisphosphonate; prg: pregnancy; NR: not reported; iv: intravenous; p.os.: orally; OP: osteoporosis; ARD: autoimmune rheumatic disease; OI: osteogenesis imperfecta; PLOP: pregnancy/lactation associated osteoporosis; CS: corticosteroids; AZA: azathioprine; SFZ: sulfasalazine; CH: chemotherapy.